▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3152 by analyst upside · 2026-08-12
ABBV
AbbVie Inc.
Healthcare · Market Cap $442B · P/E 70.4x
ANALYST PRICE TARGET
+10.1%
implied upside to consensus target
Current Price $250.09
Consensus Target $275.39
Bull Target $328.0
Bear Target $200.0
Analysts Covering 28
ANALYST CONSENSUS - BUY
Strong Buy
7
Buy
14
Hold
5
Sell
2
52-Week Low $190.75
52-Week High $267.47
YTD Return +11.6%
FUNDAMENTALS
Market Cap $442B
P/E Ratio (TTM) 70.4x
Forward P/E 15.4x
EPS (TTM) $3.55
PEG Ratio 0.41
Dividend Yield 2.79%
Revenue (TTM) $64.4B
Profit Margin 9.8%
52-WEEK RANGE
52-Week Low $190.75
52-Week High $267.47
Current Price $250.09
Bear Target $200.0
Bull Target $328.0
● Now $250.09 ● Target $275.39
TRADING DATA
Avg Volume 6.8M
YTD Return +11.6%
Analyst Count 28
Consensus Buy
Upside to Target +10.1%
Last Updated 2026-08-12

ANALYST SUMMARY

AbbVie Inc. (ABBV) is currently trading at $250.09 with a Wall Street consensus price target of $275.39, implying potential upside of 10.1% over the next 12 months. 28 analysts currently cover ABBV, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $328.0, while the most cautious has a target of $200.0.

ABBV operates in the Healthcare sector with a market capitalisation of $442B. The stock is up 11.6% year-to-date and is currently trading near the upper end of its 52-week range of $190.75 – $267.47.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

UNH +18.2%
UnitedHealth Group Incorporated
$365B · P/E 30.3x · Buy
TMO +4.4%
Thermo Fisher Scientific Inc
$224B · P/E 32.5x · Buy
AZN +34.6%
AstraZeneca PLC
$246B · P/E 23.7x · Buy
LLY +6.9%
Eli Lilly and Company
$1.08T · P/E 40.8x · Buy
AMGN -7.9%
Amgen Inc.
$224B · P/E 25.7x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for ABBV, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Evercore ISI Group - Reiterated
Outperform → Outperform 2026-05-15 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-05-14 14% win rate (7 calls)
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-05-04 Building track record
Guggenheim reit
Buy → Buy 2026-05-01 62% win rate (8 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2026-04-30 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-04-30 Building track record
Cantor Fitzgerald reit
Overweight → Overweight 2026-04-30 40% win rate (10 calls)
Piper Sandler - Reiterated
Overweight → Overweight 2026-04-23 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
60
out of 100
Coverage depth
26/30
Consensus clarity
20/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →